NeoGenomics Q1 2024 Earnings Report

NeoGenomics EPS Results

• Actual EPS: -$0.08
• Consensus EPS: -$0.07
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

NeoGenomics Revenue Results

• Actual Revenue: $156.24 million
• Expected Revenue: $149.82 million
• Beat/Miss: Beat by +$6.42 million
• YoY Revenue Growth: N/A

NeoGenomics Announcement Details

• Quarter: Q1 2024
• Date: 4/30/2024
• Time: N/A

NeoGenomics (NASDAQ:NEO) operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.